SEC Company Response from GALECTIN THERAPEUTICS INC (GALT) (CIK 0001133416) (GALT) — Aug 20, 2019
GALECTIN THERAPEUTICS INC (GALT) (CIK 0001133416)
Date: Aug. 20, 2019 · CIK: 0001133416 · Accession: 0001193125-19-224832
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-233193
Letter
Re: Galectin Therapeutics, Inc.
VIA EDGAR
August 20,
Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, N.E.
Washington, D.C.
Registration on Form S-3
File No. 333-233193
Ladies and Gentlemen:
In accordance with Rules 460 and 461 under the Securities Act of 1933, as amended, the undersigned respectfully requests that the effective date of the above-referenced Registration Statement be accelerated so that the same will become effective at 9:00 AM on August 22, 2019, or as soon thereafter as is practicable.
If you have any further comments or require any further information or if any questions should arise in connection with this submission, please call Mr. Robert Tritt at (404) 527-8130 or Mr. Brian Lee at (212) 768-6926 at Dentons US, LLP.
Sincerely,
/s/ Jack W. Callicutt.
Show Raw Text
CORRESP 1 filename1.htm CORRESP VIA EDGAR August 20, 2019 Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Galectin Therapeutics, Inc. Registration on Form S-3 File No. 333-233193 Ladies and Gentlemen: In accordance with Rules 460 and 461 under the Securities Act of 1933, as amended, the undersigned respectfully requests that the effective date of the above-referenced Registration Statement be accelerated so that the same will become effective at 9:00 AM on August 22, 2019, or as soon thereafter as is practicable. If you have any further comments or require any further information or if any questions should arise in connection with this submission, please call Mr. Robert Tritt at (404) 527-8130 or Mr. Brian Lee at (212) 768-6926 at Dentons US, LLP. Sincerely, /s/ Jack W. Callicutt. Jack W. Callicutt Chief Financial Officer